Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Kidney Neoplasms 2Carcinoma, Renal Cell 2Urinary Bladder Neoplasms 1Urethral Neoplasms 1Ureteral Neoplasms 1Testicular Neoplasms 1Testicular Germ Cell Tumor 1Pheochromocytoma 1Paraganglioma 1Neoplasms, Germ Cell and Embryonal 1Gastrointestinal Stromal Tumors 1Carcinoma, Transitional Cell 1

Interventions

Etoposide 30Carboplatin 30Cisplatin 23Ifosfamide 22Filgrastim 22Paclitaxel 18Peripheral Blood Stem Cell Transplantation 16Bleomycin 13Cyclophosphamide 11Radiotherapy 8Thiotepa 7Magnetic Resonance Spectroscopy 6Gemcitabine 6pegfilgrastim 5Therapeutics 5Polymerase Chain Reaction 5Melphalan 5Granulocyte Colony-Stimulating Factor 5Flow Cytometry 5Busulfan 5etoposide phosphate 4Temozolomide 4Psychiatric Rehabilitation 4Oxaliplatin 4Dexamethasone 4sargramostim 3Vinblastine 3Taxes 3Surveys and Questionnaires 3Methylprednisolone 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Testicular Neoplasms × guadecitabine × Genitourinary × Clear all
NCT02429466 2020-09-23

Study of the Hypomethylating Drug Guadecitabine (SGI-110) Plus Cisplatin in Relapsed Refractory Germ Cell Tumors

Indiana University

Phase 1 Completed
14 enrolled
Genitourinary

Testicular Germ Cell Tumor, Neoplasms, Germ Cell and Embryonal, Testicular Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡